Compare Crispr Therapeutics AG (CRSP) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Estee Lauder Companies Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Estee Lauder Companies Inc trades at $98.05 (market cap $34.17B). The key difference: Estee Lauder Companies Inc is far larger — about 7× Crispr Therapeutics AG's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Estee Lauder Companies Inc for 122 Days on average.
| CRSP | EL | |
|---|---|---|
Market Cap | $4.88B | $34.17B |
Volume | 2,861,747 | 3,921,497 |
Sector | Health | Consumer Staples |
52-Week High | $73.97 | $119.61 |
52-Week Low | $44.34 | $67.23 |
Typical Hold Time | 77 Days | 122 Days |
Enterprise Value | $3.30B | $39.92B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
Estée Lauder (EL) trades at $94.32, down 0.14% with neutral technical signals. The company shows mixed fundamentals with a high P/E of 188.64 but strong gross margins of 75.5%. Recent earnings beats and a $0.35 dividend signal management confidence, though 2025 saw a net loss of $1.13B. Analyst consensus is evenly split between Buy and Hold with a $103 price target.
EL faces execution risks amid competitive pressures, but strategic partnerships in AI and leadership changes may support a turnaround. The stock offers potential upside to analyst targets if margin improvements and revenue growth materialize, though high valuation and recent profitability challenges warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
